The company, which is among the world’s top biosimilars manufacturers, remains in a wait-and-watch mode, while exploring partnerships for manufacturing in the US if required, Shaw said.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.